BIVI Biovie Inc
Price (delayed)
$2.96
Market cap
$18.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.4
Enterprise value
-$3.87M
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of
Highlights
The EPS has grown by 43% YoY and by 20% from the previous quarter
BIVI's debt is down by 39% YoY and by 18% QoQ
BIVI's equity has surged by 153% since the previous quarter but it is down by 13% year-on-year
BIVI's quick ratio has soared by 68% from the previous quarter but it is down by 11% YoY
Key stats
What are the main financial stats of BIVI
Market
Valuations
Earnings
Shares outstanding
6.1M
Market cap
$18.06M
Enterprise value
-$3.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$32.73M
EBITDA
-$32.5M
Free cash flow
-$35.23M
Per share
Balance sheet
Liquidity
EPS
-$9.4
Free cash flow per share
-$7.86
Book value per share
$4.75
Revenue per share
$0
TBVPS
$6.91
Total assets
$31.77M
Total liabilities
$12.85M
Debt
$8.42M
Equity
$18.93M
Working capital
$18.06M
Debt to equity
0.44
Current ratio
2.45
Quick ratio
2.43
Net debt/EBITDA
0.67
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-132.6%
Return on equity
-301.6%
Return on invested capital
-1,521.9%
Return on capital employed
-169.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIVI stock price
How has the Biovie stock price performed over time
Intraday
0.34%
1 week
2.42%
1 month
-8.92%
1 year
-90.75%
YTD
-76.51%
QTD
-26.18%
Financial performance
How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.37M
Net income
-$36.29M
Gross margin
N/A
Net margin
N/A
The net income is up by 26% year-on-year and by 16% since the previous quarter
The company's operating income rose by 14% QoQ and by 12% YoY
Growth
What is Biovie's growth rate over time
Valuation
What is Biovie stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY and by 20% from the previous quarter
BIVI's equity has surged by 153% since the previous quarter but it is down by 13% year-on-year
The price to book (P/B) is 93% lower than the last 4 quarters average of 8.6
Efficiency
How efficient is Biovie business performance
Biovie's ROIC has plunged by 189% YoY and by 121% from the previous quarter
BIVI's ROE is up by 12% YoY and by 9% QoQ
The company's return on assets rose by 9% YoY and by 3.8% QoQ
Dividends
What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIVI.
Financial health
How did Biovie financials performed over time
Biovie's total assets is 147% more than its total liabilities
BIVI's quick ratio has soared by 68% from the previous quarter but it is down by 11% YoY
Biovie's current ratio has surged by 67% QoQ but it has decreased by 11% YoY
BIVI's debt is 56% lower than its equity
BIVI's equity has surged by 153% since the previous quarter but it is down by 13% year-on-year
BIVI's debt to equity has plunged by 68% from the previous quarter and by 31% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.